Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pinealoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neoplasms, Neuroepithelial 1Neoplasm Metastasis 1Meningioma 1Medulloblastoma 1Gliosarcoma 1Glioma, Subependymal 1Glioblastoma 1Familial ependymoma 1Ependymoma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × Verteporfin × Clear all
NCT02939274 2018-07-20

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

Rogers Sciences Inc.

Phase 2 Unknown
15 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡